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Abstract: 
        Acute Coronary Syndrome is one of the leading causes of morbidity and mortality 
in India and in worldwide. The thyroid hormonal changes could result in the functional 
derangement of the cellular metabolism and affecting almost all the organs, the heart in 
particular. The thyroidal hormonal change occurring in the setting of acute stress 
condition like sepsis, acute coronary syndrome etc., is termed as Sick Euthyroid 
Syndrome.  This condition is characterized by low T3, raised rT3 and normal levels of 
T4, FT3, FT4 and TSH. This change in thyroid function is thought to be associated with 
the mechanism involved in maintaining energy in face of altered systemic homeostasis 
caused by the acute ischemic event or directly related to inflammatory cytokines, acting 
as an inflammatory marker or both. This study assessed the prevalence of Sick Euthyroid 
Syndrome (SES) in patients with Acute Coronary Syndrome (ACS). This study also 
assessed the distribution of SES in ACS and the correlation between thyroid hormone 
profiles with the outcome. The prevalence of the Sick Euthyroid Syndrome (SES) is as 
high as 25% i.e. one quarter of ACS patients had SES. The prevalence of SES in old age 
group was low as compared to younger population. Sick Euthyroid state significantly 
associated with High BMI, CRP positivity and this condition associated with worst 
outcome. Sick Euthyroid state not correlated significantly with sex, diabetic state, 
hypertension, dyslipidemia and smoking. The T3 and rT3 levels well correlated with the 
poor outcome among  Sick Euthyroid Syndrome patients. Also, the Sick Euthyroid state 
significantly associated with poor outcome. Hence the Sick Euthyroid State serves as an 
important predictor of worst prognosis in patients with Acute Coronary Syndrome. 
  
 
 
 
 
      
 INTRODUCTION 
Coronary artery disease (CAD) is the leading cause of mortality and 
morbidity in the world and acute coronary syndromes (ACS), which 
encompass unstable angina (UA), non-ST-segment elevation myocardial 
infarction (NSTEMI) and ST-segment elevation myocardial infarction 
(STEMI), are the commonest causes of mortality in patients with CAD. With 
the introduction of a huge armamentarium of invasive and noninvasive 
therapeutic strategies, the mortality related to ACS has significantly reduced 
in the developed world over the past  20 years. But the mortality remains high 
among Indians. Acute coronary syndrome (ACS) represents the clinically 
manifest acute myocardial ischemia. 
Several studies have shown the effect of thyroid hormones on 
morbidity and mortality from heart failure, systemic arterial hypertension, 
atherosclerosis, dyslipidemia and cardiopulmonary surgeries. 
Multiple alterations in serum thyroid function test findings have been 
recognized in patients with a wide variety of NTI (nonthyroidal illnesses) 
without evidence of  preexisting thyroid or hypothalamic-pituitary disease. 
 
 
 
 The changes observed  in these situations have been classified as ―Sick 
Euthyroid Syndrome‖, consisting of low total T3 and/or free T3, increased 
reverse T3 (rT3), and normal TSH, T4 and free T4 levels. This syndrome has 
been well described in acute coronary syndrome affecting the prognosis. 
This change in thyroid function is thought to be associated with the 
mechanism involved in maintaining energy in face of altered systemic 
homeostasis caused by the acute ischemic event or directly related to 
inflammatory cytokines, acting as an inflammatory marker, or both. 
          The present work is a modest attempt to study the prevalence of Sick 
Euthyroid State in patients with acute coronary syndrome. 
 
 
 
 
 
 
 
  
AIM OF THE STUDY 
1.      To study the prevalence of Sick Euthyroid Syndrome in patients with 
Acute Coronary Syndrome.  
2.      To study the distribution of Sick Euthyroid Syndrome according to age, 
sex, BMI, type of ACS, diabetes, hypertension, dyslipidemia, smoking, 
CRP status in patients with ACS. 
3. To Study the correlation between the thyroid profile and the outcome 
among the SES patients with Acute Coronary Syndrome. 
 
 
  
 REVIEW OF LITERATURE 
ACUTE CORONARY SYNDROME: 
Acute coronary syndrome (ACS)
1
 refers to any constellation of clinical 
symptoms that are compatible with acute myocardial ischemia. ACS is 
divided into ST- elevated myocardial infarction (STEMI), 
 non-ST elevated myocardial infarction (NSTEMI), and unstable angina 
(UA).        
 
STEMI results from complete and prolonged occlusion of an epicardial 
coronary blood vessel and is defined based on ECG criteria. 
 NSTEMI usually results from severe coronary artery narrowing, 
transient occlusion, or microembolization of thrombus and/or atheromatous
2
 
material. NSTEMI is defined by an elevation of cardiac biomarkers
3
 in the 
absence of ST elevation. The syndrome is termed UA in the absence of 
elevated cardiac enzymes and ST elevation.  
History, physical examination, ECG, biomarkers, ECHO all remain 
important tools to make an appropriate diagnosis. The management of ACS 
should focus on rapid diagnosis, risk stratification, and institution of therapies 
that restore coronary blood flow and reduce myocardial ischemia. 
PROBLEM STATEMENT: 
Coronary heart disease (CHD) is the leading cause of death in India 
and the leading cause of death worldwide.
4
 Previously thought to affect 
primarily high-income countries, CHD now leads to more death and disability 
in low- and middle-income countries, such as India, with the rates that are 
increasing disproportionately compared to high-income countries.  With the 
epidemiologic transition
5
, the Cardio vascular disease (CVD) burden 
continues to rise in developing countries including India. The projected rise in 
disease burden due to CVD is expected to make it the prime contributor of 
total mortality and morbidity.  
The distribution and prevalence of CHD in India: 
[Indian Atlas of CHD in India (Gupta, 2008)]
6
 
 In 2000, there were an estimated 29.8 million people with CHD in 
India, out of a total estimated population of 1.03 billion people, or a nearly 
3% overall prevalence. (Gupta, 2008, India Census, 2001)
7
. Unadjusted CHD 
rates have ranged from 1.6% to 7.4% in rural populations and 1% to 13.2% in 
urban populations. (Gupta, 2008)
8
 
CHD prevalence appears to be worsening in India. In developed 
countries, ischemic heart disease is predicted to rise 30-60% between 1990 
and 2020. In developing countries, rates are predicted to increase by 120% in 
women and 137% in men from 1990 to 2020. (Murray, 1997) Sixty percent of 
the world‘s patients with heart disease, including CHD, are predicted to live 
in India by 2010. (Ghaffar, 2004)
9
. Demographic and health transitions, gene-
environmental interactions and early life influences of fetal malnutrition are 
the likely causes  of increased CVD burden in India  
CHD affects Indians with greater frequency and at a younger age than 
counterparts in developed countries,as well as many other developing 
countries thereby having a greater economic impact on low- and middle-
income countries. Age-standardized CVD death rates in people 30-69 years 
old are 180 per 100,000 in Britain, 280 per 100,000 in China, and 405 per 
100,000 in India.
10
  Also, 50% of CHD-related deaths in India occur in people 
<70 years of age, whereas only 22% of CHD-related deaths in Western 
countries occur in this age group. (Gaziano, 2006) 
 Mortality Associated with CHD: 
Almost 2.6 million Indians are predicted to die due to  coronary heart 
disease (CHD), which constitutes 54.1% of all CVD deaths in India by 2020.  
PATHOGENESIS: 
The process central to the initiation of an acute coronary syndrome is 
disruption of an atheromatous plaque
11
. Fissuring or rupture of these plaques 
and consequent exposure of core constituents such as lipid, smooth muscle, 
and foam cells leads to the local generation of thrombin and deposition of 
fibrin.  
This in turn promotes platelet aggregation and adhesion and the 
formation of  intracoronary thrombus. 
 
 Plaque disruption exposes substances that promote platelet activation 
and aggregation, thrombin generation, and ultimately thrombus formation. 
The resultant thrombus interrupts blood flow and leads to an imbalance 
between oxygen supply and demand and, if this imbalance is severe and 
persistent, to myocardial necrosis.
12 
When plaque disruption occurs, a sufficient quantity of thrombogenic 
substances is exposed, and the coronary artery lumen may become obstructed 
by a combination of platelet aggregates, fibrin, and red blood cells that may 
produce an extensive thrombus filling a large segment of the infarct-related 
artery. An adequate collateral network that prevents necrosis from occurring 
can result in clinically silent episodes of coronary occlusion. Disruption of 
plaques is now considered to underlie most acute coronary syndromes (ACS).  
STEMI: 
HISTORY AND PHYSICAL EXAMINATION: 
Symptoms 
The classic symptom of MI is precordial or retrosternal discomfort that 
is commonly described as a pressure, crushing, aching, or burning sensation. 
Radiation of the discomfort to the neck, back, or arms frequently occurs, and 
the pain is usually persistent. The discomfort typically achieves maximum 
intensity over several minutes and can be associated with nausea, diaphoresis, 
generalized weakness, and a fear of impending death. Some patients, 
 particular the elderly, may also present with syncope, unexplained nausea and 
vomiting, acute confusion, agitation, or palpitations.
13
 
 Approximately 20 percent of MI patients are asymptomatic or have 
atypical symptoms that are not initially recognized. Painless myocardial 
infarction occurs more frequently in the elderly, women, diabetics, and 
postoperative patients. These patients tend to present with dyspnea or frank 
congestive heart failure as their initial symptom. 
Physical Examination 
Patients can appear anxious and uncomfortable. Those with substantial 
left ventricular (LV) dysfunction at presentation may have tachycardia, 
pulmonary rales, tachypnea, and a third heart sound. The presence of a mitral 
regurgitant murmur suggests ischemic dysfunction of the mitral valve 
apparatus, rupture, or ventricular remodeling. 
In patients with right ventricular infarction, increased jugular venous 
pressure, Kussmaul sign (rise in jugular venous pressure with inspiration), and 
a right ventricular third sound may be present.
14
 Such patients virtually 
always have inferior infarctions, usually without evidence of left-heart failure, 
and may have exquisite blood pressure sensitivity to nitrates or hypovolemia. 
In patients with extensive left ventricular dysfunction, shock is indicated by 
 hypotension, diaphoresis, cool skin and extremities, pallor, oliguria, and 
possible confusion
15
. 
DIAGNOSIS: 
 Revised Definition of Myocardial Infarction (MI)
16
 
Criteria for Acute, Evolving, or Recent MI 
Either of the following criteria satisfies the diagnosis for acute, 
evolving, or recent MI: 
1.     Typical rise and/or fall of biochemical markers of myocardial necrosis 
with at least one of the following:  
a)     Ischemic symptoms  
b)     Development of pathological Q waves in the ECG  
c)     ECG changes indicative of ischemia (ST segment elevation or 
depression)  
d)     Imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormality 
2.     Pathological findings of an acute myocardial infarction 
Biomarkers: 
Cardiac troponin (CTn) is the biomarker of choice because it is the 
most sensitive and specific marker of myocardial injury/ necrosis available.  
 Troponin levels usually increase after 3-4 hours. If the first blood 
sample for CTn is not elevated, a second sample should be obtained after 6-9 
h, and sometimes a third sample after 12 to 24 hours is required. Troponin 
level may remain elevated up to 2 weeks. Elevated CTn values signal a higher 
acute risk and an adverse long term prognosis. Creatine Kinase MB is less 
sensitive and specific for the diagnosis of NSTE ACS. However, it remains 
useful for the diagnosis of early infarct extension (reinfarction) and peri-
procedural MI because of its short half life. NT-Pro BNP is helpful in 
assessing left ventricular failure patients.
17
 
Biomarkers for the Evaluation of Patients with ST-Elevation Myocardial 
Infarction 
Biomarker 
Molecular 
Weight (D) 
Range of 
Times to 
Initial 
Elevation (hr) 
Mean Time to Peak 
Elevations 
(Nonreperfused) 
Time to 
Return to 
Normal 
Range 
 
MB-CK 86,000 3–12 24 hr 48-72 hr 
cTnI 23,500 3–12 24 hr 5-10 d 
cTnT 33,000 3–12 12 hr-2 d 5-14 d 
  
Electrocardiogram: 
Characteristically, completely occlusive thrombi in case of STEMI 
lead to a large zone of necrosis involving the full or nearly full thickness of 
 the ventricular wall in the myocardial bed subtended by the affected coronary 
artery and typically produce ST elevation on the ECG. Infarction alters the 
sequence of depolarization ultimately reflected as changes in the QRS. The 
most characteristic change in the QRS that develops in the majority of 
patients initially presenting with ST elevation is the evolution of Q waves in 
the leads overlying the infarct zone—leading to the term Q-wave infarction. 
In the minority of patients presenting with ST elevation, no Q waves develop, 
but other abnormalities of the QRS complex are frequently seen, such as 
diminution in R wave height and notching or splintering of the QRS.
17
 
The infarction process evolves through three easily recognizable 
electrocardiographic phases. These three phases and their characteristic ECG 
manifestations are as fallows
18
; 
1.  The hyperacute phase: 
             a) Increased ventricular activation time. 
             b) Increased R wave amplitude. 
             c) Slope ST segment elevation. 
             d) Tall and widened T waves.  
2.  The fully evolved phase: 
             a) A Qs or Qr complex, loss of R wave amplitude. 
             b) Coved ST segment elevation. 
             c) Symmetrical, pointed T wave inversion.   
 3.  The chronic stabilized phase: 
             a) Prominent Q waves.  
             b) Isoelectric ST segment. 
             c) Upright T wave. 
Localization of infarction: 
Infarction of the left ventricle; 
           a) The anterior wall. 
           b) The inferior wall. 
           c) The posterior wall. 
Infarction of the right ventricle; 
Echocardiography: 
Imaging evidence of new loss of viable myocardium or new regional 
wall motion abnormality is useful for the diagnosis particularly in patients 
with typical anginal pain but without ECG evidence of MI.
19
 
Echocardiography and Doppler examination should be done after 
hospitalization to assess the global left ventricular function and any regional 
wall motion abnormality.  
  
PROGNOSIS ASSESSMENT:     
Killip Classification
20 
for Patients with  
ST-Segment Elevation Myocardial Infarction 
Killip class Hospital mortality (%) 
I No congestive heart failure 6 
II Mild congestive heart failure, rales, S3, 
congestion on chest radiograph 
17 
III Pulmonary edema 38 
IV Cardiogenic shock 81 
 
APPROACH TO MANAGEMENT:   
       
 
 
 
 
 
 
 
 
 Initial Therapy in the Emergency Department: 
The initial management of patients in the emergency department 
includes the use of oxygen, aspirin, beta blockers, analgesia, nitroglycerin, 
and anticoagulation with heparin.
21
 
Reperfusion Strategies 
The main goal of STEMI management is rapid reperfusion to establish 
coronary blood flow to ischemic myocardium. Currently, there are three main 
reperfusion strategies
22
: thrombolytic therapy, primary PCI, and thrombolytic-
facilitated primary PCI. 
UA and NSTEMI: 
HISTORY AND PHYSICAL EXAMINATION:              
Symptoms:           
The typical clinical presentation of NSTE ACS is retro sternal pressure 
or heaviness (―angina‖) radiating to the left arm, neck or jaw which may be 
intermittent (usually lasting several minutes) or persistent. There are several 
atypical symptoms and these include epigastric pain, recent onset indigestion, 
stabbing chest pain and are often observed in younger and older patients, in 
women, and in patients with diabetes.       
The following clinical presentations are usually included in unstable 
angina,
23 
  Prolonged (> 20 min) anginal pain at rest. 
 New onset (de novo) severe angina (class III of the classification of 
Canadian Cardiovascular Society (CCS). 
 Recent destabilization of previously stable angina with at least CCS III 
angina characteristics (crescendo angina) or 
 Post MI angina. 
Physical examination:    
The clinical examination is frequently normal. The presence of 
tachycardia, heart failure or haemodynamic instability must prompt the 
physician to expedite the diagnosis and treatment of patients. It is important to 
identify clinical circumstances that may precipitate or exacerbate NSTE- 
ACS, such as anemia, infection, fever and metabolic or thyroid disorders. An 
important goal of physical examination is to exclude non-cardiac causes of 
chest pain and non-ischemic cardiac disorders (e.g. pulmonary embolism, 
aortic dissection, pericarditis, valvular heart disease) or extra cardiac causes. 
DIAGNOSIS: 
Electrocardiogram: 
In NSTE ACS, ECG may show ST segment deviation, T wave changes 
or may remain normal. In several studies, around 5% patients with normal 
 ECG who were discharged from the emergency department were ultimately 
found to have acute MI or UA.  ST segment shifts and T wave changes are the 
ECG indicators of unstable CAD. The number of leads showing ST 
depression and the magnitude of ST depression are indicative of the extent 
and severity of ischemia and correlate with the prognosis.  ST depression of > 
2 mm carries an increased mortality risk. Inverted T waves, especially if 
marked (greater than or equal to 2mm (0.2 mv) also indicate UA/ NSTEMI. Q 
waves suggesting prior MI indicate a high likelihood of IHD. 
Biomarkers: 
Cardiac troponin (CTn) is the biomarker of choice because it is the 
most sensitive and specific marker of myocardial injury/ necrosis available.  
Creatine Kinase MB is less sensitive andspecific for the diagnosis of NSTE 
ACS. However, it remains useful for the diagnosis of early infarct extension 
(reinfarction) and peri-procedural MI because of its short half life. NT-Pro 
BNP is helpful in assessing left ventricular failure patients. Biomarkers will 
be negative in UA. 
Echocardiography: 
Echocardiography and Doppler examination should be done after 
hospitalization to assess the global left ventricular function and any regional 
wall motion abnormality. Echocardiography also helps in excluding other 
causes of chest pain. 
PROGNOSIS ASSESSMENT: 
 NSTE ACS includes a heterogeneous group of patients with a highly 
variable prognosis. The risk stratification is necessary for prognosis 
assessment and treatment. A simple TIMI risk score11 has been validated and 
can be used.A TIMI score <3 usually indicates a low risk and a TIMI score = 
3-4  indicates intermediate risk, where as score of 5-7 is high risk. 
In general, patients having multiple coronary risk factors, advanced 
age, rest angina, clinical left ventricular (LV) dysfunction, prior history of 
percutaneous coronary intervention (PCI) or coronary artery bypass graft 
surgery (CABGS) or patients with dynamic ST-T changes and elevation of 
troponin or CK-MB indicates myocyte necrosis and a high risk. There are 
other risk models based on PURSUIT trial and GRACE registry. 
THE TIMI RISK 
24
SCORE FOR Non STEMI 
 
Characteristics                                                                 score 
 
History: Age  > 65 yrs.       1 
               >3 risk factor for CAD                                        1 
              (DM, HT, Dyslipidemia,  Family h/O                 
              Known CAD      1 
              H/O aspirin in last 7  days    1 
Presentation 
              2 anginal events < 24 hrs               1 
              ST deviation       > o.5 mm    1 
              Elevated cardiac enzymes    1 
RISK SCORE TOTAL                                         0-7   
 APPROACH TO MANAGEMENT:     
The aims of therapy for UA/NSTEMI patients are to control  
symptoms and prevent further episodes of myocardial ischemia and/or 
necrosis.  Beta blockers, nitrates, and, to a lesser extent, calcium channel 
blockers reduce the risk of recurrent ischemia. Revascularization eliminates 
ischemia in many patients.  
              Hospitalized moderate- to high-risk ACS patients should be treated 
with aspirin (ASA), clopidogrel, antithrombin therapy, a beta blocker, statin, 
and, in selected individuals, a GPIIb/IIIa inhibitor. Furthermore, critical 
decisions are required regarding the angiographic strategy. One option, 
commonly termed the early invasive strategy, incorporates an angiographic
25
 
approach in which coronary angiography and revascularization are performed 
unless a contraindication exists. The alternative approach is the early 
conservative strategy with angiography reserved for patients with recurrent 
ischemia at rest or a high-risk noninvasive evaluation for ischemia.  
Regardless of the angiographic strategy, an assessment of LV function 
should be strongly considered.  When coronary angiography is not scheduled, 
the patient is evaluated at rest and/or with stress for inducible myocardial 
ischemia or LV systolic dysfunction 
 
 
 SECONDARY PREVENTION: 
Modifiable Risk Factors for the  
Prevention of Cardiovascular Disease
26
 
This is most important to prevent further episodes of ACS  thereby 
reducing the morbidity and mortality. 
Class 1 risk factors & intervention: 
Smoking  – Cessation of smoking strongly advocated as this 
will result in 60% reduction in CHD risk by three 
years. 
Dyslipidemia  – Dietary changes combined with statins strongly 
recommended. 
Hypertension  - Dietary advice , anti hypertensive agents 
Aspirin in secondary  
prevention  - following MI  
Beta blockers  - following MI 
ACE inhibitors     - Following MI, LV dysfunction 
 
Class 2 risk factors & intervension: 
Diabetes - Dietary advice, exercise, Drugs 
Obesity - Weight reduction, life style modification Moderate 
alcohol consumption 
Class 3 risk factors and interventions are currently under active investigation 
Menopause, hormone replacement, Dietary supplements, Psychological 
factors, Novel biochemical and genetic markers (fibrinogen, homocysteine, 
Lp(a) etc.) Additional observational data needed to clarify role of these 
factors in clinical practice. 
  
THYROID 
The thyroid gland produces two important hormones, thyroxine (T4) 
and triiodothyronine (T3)
27.
 Acting through nuclear receptors, these  
hormones play a critical role in cell differentiation during development and 
help  maintain thermogenic and metabolic homeostasis in the adult.  T3 and 
T4 are synthesized from both iodine and tyrosine. The thyroid also   produces  
calcitonin, which plays a role in calcium homeostasis. 
Thyroid Hormone Synthesis, Metabolism, and Action 
Thyroid Hormone Synthesis: 
Thyroid hormones are derived from thyroglobulin, a large iodinated 
glycoprotein. After secretion into the thyroid follicle, Tg is iodinated on 
tyrosine residues that are subsequently coupled via an ether linkage. Reuptake 
of Tg into the thyroid follicular cell allows proteolysis and the release of 
newly synthesized T4 and T3. 
 
 
 
 
 Steps in thyroid hormone synthesis 
1)  Iodide uptake: 
Iodide uptake is a first step in thyroid hormone synthesis. Ingested 
iodine is bound to serum albumin. The thyroid gland extracts iodine from the 
circulation. Iodide uptake is mediated by the Na
+
/I
–
 symporter (NIS), which is 
expressed at the basolateral membrane of thyroid follicular cells. NIS is most 
highly expressed in the thyroid gland. The iodide transport mechanism is 
highly regulated, allowing adaptation to variations in dietary supply. The 
selective expression of NIS in the thyroid allows isotopic scanning, treatment 
of hyperthyroidism, and ablation of thyroid cancer with radioisotopes of 
iodine, without significant effects on other organs. Mutation of the NIS gene 
is a rare cause of congenital hypothyroidism, underscoring its importance in 
thyroid hormone synthesis. Another iodine transporter, pendrin, is located on 
the apical surface of thyroid cells and mediates iodine efflux into the lumen. 
Mutation of the PENDRIN
28
 gene causes Pendred syndrome, a disorder 
characterized by defective organification of iodine, goiter, and sensorineural 
deafness. The recommended average daily intake of iodine is 150 g/d for 
adults, 90–120 g/d for children and 200 g/d for pregnant women. Urinary 
iodine is >10 g/dL in iodine-sufficient populations. 
 
 2)  Organification: 
After iodide enters the thyroid, it is trapped and transported to the 
apical membrane of thyroid follicular cells, where it is oxidized in an 
organification reaction that involves TPO and hydrogen peroxide. The 
reactive iodine atom is added to selected tyrosyl residues within Tg, a large 
(660 kDa) dimeric protein that consists of 2769 amino acids
30
 
3)  Coupling:The iodotyrosines in Tg are then coupled via an ether 
linkage in a reaction that is also catalyzed by TPO. Either T4 or T3 can be 
produced by this reaction, depending on the number of iodine atoms present 
in the iodotyrosines. 
4)  Storage:The synthesized hormones stored in the follicle. 
5)  Release:Tg is taken back into the thyroid cell, where it is processed in 
lysosomes to release T4 and T3. 
 
 
 
 
 
 
  
 
Regulation of the thyroid hormone synthesis 
TSH, secreted by the thyrotrope cells of the anterior pituitary, plays a 
pivotal role in control of the thyroid axis and serves as the most useful 
physiologic marker of thyroid hormone action. The extent and nature of 
carbohydrate modification are modulated by thyrotropin-releasing hormone 
(TRH) stimulation and influence the biologic activity of the hormone. 
The thyroid axis is a classic example of an endocrine feedback loop.  
Hypothalamic TRH stimulates pituitary production of TSH, which, in turn, 
stimulates thyroid hormone synthesis and secretion. Thyroid hormones feed 
back to inhibit TRH and TSH production. The "set-point" in this axis is 
established by TSH. TRH is the major positive regulator of TSH synthesis 
and secretion. TSH is measured using immunoradiometric assays
31
 that are 
highly sensitive and specific. These assays readily distinguish between normal 
and suppressed TSH values; thus, TSH can be used for the diagnosis of 
hyperthyroidism (low TSH) as well as hypothyroidism (high TSH). 
Other Factors that Influence Hormone Synthesis and Release: 
Although TSH is the dominant hormonal regulator of thyroid gland 
growth and function, a variety of growth factors, most produced locally in the 
 thyroid gland, also influence thyroid hormone synthesis. These include 
insulin-like growth factor I (IGF-I), epidermal growth factor, transforming 
growth factor (TGF-), endothelins, and various cytokines. 
Thyroid Hormone Transport and Metabolism: 
T4 is secreted from the thyroid gland in about twentyfold excess over. 
T3. Both hormones are bound to plasma proteins, including thyroxine-binding 
globulin (TBG); transthyretin (TTR), and albumin. The plasma-binding 
proteins increase the pool of circulating hormone, delay hormone clearance, 
and may modulate hormone delivery to selected tissue sites. The 
concentration of TBG is relatively low (1–2 mg/dL), but because of its high 
affinity for thyroid hormones (T4 > T3), it carries about 80% of the bound 
hormones. Albumin has relatively low affinity for thyroid hormones but has a 
high plasma concentration  (~3.5 g/dL), and it binds up to 10% of T4 and 30% 
of T3. TTR carries about 10% of T4 but little T3.  When the effects of the 
various binding proteins are combined, approximately 99.98% of T4 and 
99.7% of T3 are protein-bound.  
Because T3 is less tightly bound than T4, the fraction of unbound T3 is 
greater than unbound T4, but there is less unbound T3 in the circulation 
because it is produced in smaller amounts and cleared more rapidly than T4. 
The unbound, or free, concentrations of the hormones are ~2 x 10
–11
M for T4 
 and ~6 x 10
–12
M for T3, which roughly correspond to the thyroid hormone 
receptor binding constants for these hormones. The unbound hormone is 
thought to be biologically available to tissues. 
Deiodinases 
T4 may be thought of as a precursor for the more potent T3. T4 is 
converted to T3 by the deiodinase enzymes. Type I deiodinase, which is 
located primarily in thyroid, liver, and kidney, has a relatively low affinity for 
T4. Type II deiodinase has a higher affinity for T4 and is found primarily in 
the pituitary gland, brain, brown fat, and thyroid gland. Expression of type II 
deiodinase allows it to regulate T3 concentrations locally, a property that may 
be important in the context of levothyroxine (T4) replacement. Type II 
deiodinase is also regulated by thyroid hormone; hypothyroidism induces the 
enzyme, resulting in enhanced T4 T3 conversion in tissues such as brain and 
pituitary. T4 T3 conversion is impaired by fasting, systemic illness or acute 
trauma, oral contrast agents, and a variety of medications (e.g., 
propylthiouracil, propranolol, amiodarone, glucocorticoids).
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 Type III 
deiodinase inactivates T4 and T3 and is the most important source of reverse 
T3 (rT3). Massive hemangiomas that express type III deiodinase are a rare 
cause of hypothyroidism in infants. 
 THYROID HORMONE ACTION: 
Thyroid Hormone Transport 
Circulating thyroid hormones enter cells by passive diffusion and via 
the monocarboxylate 8 (MCT8) transporter. After entering cells, thyroid 
hormones act primarily through nuclear receptors. 
Physiological effects of thyroid hormones: 
Heart  :  Increases number of β adrenergic receptors and 
enhances response to catecholamines 
Adipose tissue : Stimulate lipolysis 
Muscle  : Increases protein breakdown 
Bone  : Promote growth and development 
Nervous system  :  Promote normal brain development 
Gut  : Increases carbohydrate absorption 
Lipoprotein  : Stimulate LDL receptors 
Others  : Increases metabolic rate and oxygen consumption 
 SICK EUTHYROID SYNDROME: 
Definition:  
Disturbances in the circulating concentrations of thyroid hormones and 
TSH assays arising in systemic non-thyroid illnesses without preexisting 
hypothalamic-pituitary- thyroid gland dysfunction and normalizing after 
recovery.
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Classification 
 Low serum T3, normal T4. The most common biochemical 
abnormality, it is seen in approximately 70% hospitalized patients. 
T3 reduced by about  50%, rT3increased (except in renal failure) due to 
its decreased clearance  as a result of reduced activity/production of 5′ 
mono-deiodinase Type 1. 
 Low serum total T3 and T4. Usually seen in severely ill patients. Free 
T4 is normal owing to inhibition of T4 binding or production of altered 
TBG. 
 High serum total T4, normal total T3. Seen in patients with liver disease 
producing increased quantities of TBG. Free T3 low or low-normal,  
rT3 high. 
 Increased serum total-T4 and TBG, normal T3 and paradoxical       
decreases in rT3. Seen in patients with HIV infection. 
 Clinical considerations 
 Drugs, used to treat the severely ill, affect thyroid physiology and these 
factors to be excluded before diagnosing SES. 
Drugs and the thyroid gland 
Drugs can alter thyroid hormone status by affecting thyroid hormone 
synthesis, transport or metabolism
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. They act at a number of sites to: 
 Block I
-
 uptake, e.g. lithium. 
 Decrease iodination of the tyrosine molecules in thyroglobulin, e.g. 
some sulfonamides and sulfonylureas. 
 Inhibit hormone secretion, e.g. lithium 
Alter thyroid binding globulin concentration and, thus, concentrations 
of ‗free‘ thyroid hormones, e.g. estrogens, clofibrate increase TBG whilst 
androgens, glucocorticoids and L-asparginase decrease TBG. 
 Alter binding to TBG or transthyretin, e.g. salicylates, phenytoin and 
some non-steroidal anti-inflammatories such as fenclofenac. 
 Decrease conversion of T4 to T3, e.g. glucocorticoids, propranolol,      
amiodarone, some iodinated radiographic contrast agents. 
 Increase hormone degradation or excretion, e.g. phenytoin,        
carbamazepine, cholestyramine. 
The most prominent alterations are low serum triiodothyronine (T3) 
and elevated reverse T3 (rT3), leading to the general term "low T3 
syndrome."  
 Thyroid-stimulating hormone (TSH), thyroxine (T4), free T4 (FT4), 
and free T4 index (FTI) also are affected in variable degrees based on the 
severity and duration of the SES. As the severity of the SES increases, both 
serum T3 and T4 levels drop and gradually normalize as the patient 
recovers
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       Sick Euthyroid State is observed in most of the acute and chronic 
illnesses. Examples of illness include the following:  
 Sepsis 
 Burns 
 CVD 
 Gastrointestinal diseases 
 Pulmonary diseases 
 Renal diseases 
 Surgery 
 Malignancy 
 Bone marrow transplantation 
Proposed mechanisms explaining abnormalities in thyroid hormone 
levels Cytokines:  
Cytokines are thought to play a role in NTI—particularly interleukin 
(IL)-1, IL-6, tumor necrosis factor (TNF)-alpha, and interferon-beta. 
 Cytokines are thought to affect the hypothalamus, the pituitary, or other 
tissues, inhibiting production of TSH, thyroid-releasing hormone (TRH), 
thyroglobulin, T3, and thyroid-binding globulins. Cytokines are also thought 
to decrease the activity of type I deiodinase and to decrease the binding 
capacity of T3 nuclear receptors.  
Deiodination: 
Peripheral deiodination of T4 to T3 is impaired, secondary to 
decreased activity of type I deiodinase enzyme, which deiodinates T4 to T3. 
Diminished enzyme activity accounts for decreased deiodination of T4 to T3.  
An alternative explanation is that reduced tissue uptake of T4 
secondary to deficiency of cytosolic cofactors (eg, nicotinamide adenine 
dinucleotide phosphate [NADPH], glutathione) results in decreased substrate 
for type I deiodinase enzyme. Type I deiodinase is a selenoprotein; because 
selenium deficiency is common in critically ill patients, some propose that 
selenium deficiency may contribute to type I deiodinase malfunction. 
Inhibition of thyroid-releasing hormone and thyroid-stimulating hormone 
secretion: Inhibition of plasma membrane transport of iodothyronines: 
Thyroxine-binding globulin decrease and desialation: T4-binding globulin 
(TBG) is a member of the serine protease inhibitors. Diminished T4 in NTI 
has been proposed to be due to low TBG caused by protease cleavage at 
inflammatory sites in acute inflammatory conditions
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 Sick Euthyroid State in ACS:  
The low T3 syndrome, the most common type of sick Euthyroid 
syndrome , once believed to be a beneficial adaptive mechanism under 
conditions of stress, has emerged as a strong prognostic determinant in 
chronic systolic heart failure. Increased mortality among patients with low T3 
syndrome has also been observed in acute myocardial infarction, a common 
precursor of chronic heart failure of ischemic origin.  
Acute myocardial infarction (AMI) may be associated with a number 
of endocrine alterations, including those of the SES which reflect the acute 
hormone response to stress and trauma. A transient decrease in T3 and 
increase in reverse (r)T3 occurs within the first 24 h, reaching the highest 
degree on the third day after the attack. The decreased nutrition during the 
first days of the myocardial infarct, the increased levels of serum cortisol, 
circulating free fatty acids, free radicals, cytokines are some of the factors 
which may contribute to the 50-monodeiodinase inhibition. Less prominent 
are the alterations of T4 and thyrotropin  (TSH) which appear to be non-
significantly changed in most of the patients with acute myocardial infarct. It 
is known from several studies that several cytokines can be found elevated in 
patients with cardiac ischemia or AMI.
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 From in vitro studies it is of 
particular interest that ischemic myocytes produce cytokines such as 
interleukin-6 (IL-6) and its synthesis is accelerated by reperfusion. 
 Interleukin-6 seemed to be an important cytokine produced by the injured 
myocytes in patients with AMI, and strong negative correlation between 
serum IL-6 concentration and left ventricular ejection fraction (LVEF) has 
been demonstrated. Similar observations have been made by studying tumor 
necrosis factor-a (TNF-a), IL-1a and soluble IL-2 receptor (sIL-2-R) which 
were found to be significantly elevated in AMI, with the highest levels noted 
in the most severe and complicated cases of myocardial infarction
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In addition, there is a gradual progression from a low T3 level to an 
advanced illness with extremely low T3 and T4 levels, which can be 
associated with high mortality. Similarly excessive decreases of T4 are linked 
with increasing mortality in AMI. There several studies support the idea that 
excessive decreases of T4 are linked with seriousness of AMI. 
 MATERIALS AND METHODS 
The present study titled "Thyroid Profile in Acute coronary 
syndrome" was carried out in the Department of Medicine and in the 
Department of cardiology, kilpauk medical college and hospital (Chennai). 
Study design : Cross sectional study. 
Period of study: November 2010 to October 2011. 
Materials :  
Questionnaire, BMI calculation, Blood pressure, TIMI score and 
Killip‘s class, CBC, CRP, FBS and PPBS, Blood Urea, Serum creatinine and 
electrolytes, Urinalysis, serial ECGs, Chest X ray, Fasting lipid profile, 
Thyroid profile (T3, T4, FT3, FT4, TSH and rT3) and echocardiography.            
Study group :  
The study group included 155 patients who were admitted in ICCU 
with the diagnosis of acute coronary syndrome. 
Inclusion criteria 
Patients with acute coronary syndrome (STEMI/ NSTEMI/ UA)  irrespective 
of their  gender, race, ethnic group, age, and clinical severity. 
 Exclusion criteria 
 Patients with known CHD with or without LV dysfunction 
 Patients with known thyroid disease 
 Patients with TSH level of <0.4 and > 4.0 μ IU/ml . 
 Patients who had received iodinated contrast agent within the last two 
weeks.   
 Patients with chronic renal failure 
 Patients with chronic obstructive pulmonary disease exacerbation 
 Patients with acute illness (sepsis, DKA, severe respiratory failure,  
and recent H/O surgery) 
 Patients with hepatic dysfunction and/ or cirrhosis 
 Patients using drugs interfering with thyroid function (amiodarone, 
propranolol, corticosteroids and oral contraceptives) 
 METHODS 
One hundred and fifty five patients admitted during November2010 to 
October 2011 in ICCU, KMC Hospital were prospectively studied. All 
patients in the study group were selected irrespective of their  age gender, 
race, ethnic group, and clinical severity. A complete history was recorded to 
fulfill the exclusion criteria and risk factors for CHD were noted.  A thorough 
physical examination was done. Risk stratification was done using TIMI score 
and Killips classes. Blood samples were taken. Echocardiography was done in 
all patients. 
Investigations: 
12 lead ECGs were taken serially.  
Complete blood count : 
RBC count: 
TC :                       DC:   
Platelet count 
Hb in gm%  
ESR 
CRP:  
Agar-Gel Precipitin-Inhibition Technique was used for estimation.  
 
 Urine analysis: 
       Sugar, albumin, deposits.   
Blood sugar: 
FBS and PPBS are estimated by Trinder‘s (Glucose oxidase) method 
and read at 505/670 nm. 
Renal function test: 
Blood urea was estimated using DAM method (Diacetyl Monoxime). 
Serum creatinine was estimated using Modified Jaffe‘s method. Serum 
electrolytes were estimated using flame photometry with ion specific 
electrodes. 
Fasting lipid profile:  Methods used were, 
For, T. Chol. - CHOD POD METHOD 
 HDL - Selective immune precipitation method 
 TGL - Enzymatic calorimetric method 
 LDL - Derived from TC and TGL values. 
 VLDL - Derived from triglyceride values 
 CPK - MB, was measured by Column Chromatography. 
Fasting thyroid profile: 
TSH was estimated using Ultrasensitive sandwich chemi luminescent 
immuno assay. 
 T4, T3, FT4 and FT3 were measured by Competitive chemi luminescent 
immuno assay reverse T3 was measured by radioimmunoassay, using the 
Serono kit. 
Echocardiography was done to look for wall motion abnormalities 
and to assess LV function. 
DEFINITIONS 
Acute coronary syndrome: 
a)  Criteria for Acute, Evolving, or Recent MI 
Either of the following criteria satisfies the diagnosis for acute, evolving, or 
recent MI: 
1. Typical rise and/or fall of biochemical markers of myocardial necrosis 
with at least one of the following:  
a) Ischemic symptoms 
b) Development of pathological Q waves in the ECG 
c) ECG changes indicative of ischemia (ST segment elevation or 
depression) 
d) Imaging evidence of new loss of viable myocardium or new regional 
wall motion abnormality 
2) Pathological findings of an acute myocardial infarction 
 
 
 b)  Unstable Angina 
Prolonged (> 20 min) anginal pain at rest. 
New onset (de novo) severe angina (class III of the classification of  
Canadian Cardiovascular Society (CCS). 
Recent destabilization of previously stable angina with at least CCS III  
angina characteristics (crescendo angina) or Post  MI angina 
Sick  Euthroid  Syndrome     
Definition: Disturbances in the circulating concentrations of thyroid 
hormones  and TSH assays arising in systemic non-thyroid illnesses without 
preexisting  hypothalamic-pituitary- thyroid gland dysfunction and 
normalizing after  recovery. 
Diabetes Mellitus Systemic Hypertension (As per the ADA 2010 
Guidelines)  
FDS ≥ 126mg/dl 
PPDS ≥ 200 mg/dl 
HBA1C ≥ 6.5  
Subjects on medications for hypertension and those who had a systolic 
blood pressure of ³ 140 mmHg and / or diastolic blood pressure ³ 90 mmHg 
were considered to have hypertension. 
Dyslipidemia 
Adult Treatment Panel III (ATP III) guidelines developed by the 
National. Cholesterol Education Program have been used to detect 
 dyslipidemia in the study subjects. Diabetes mellitus is considered as 
Coronary Heart Disease equivalent. According to the guidelines: 
Overweight and Obesity 
BMI (WHO criteria for Asian population) is used for classifying the 
subjects according to the weight status. 
BMI Group BMI(kg/m2) 
Underweight < 18.5 
Normal weight 18.5-22.9 
Overweight 23-29.9 
Obesity  30.0
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Thyroid profile 
Reference values:  
T3  70 to 100 μg/dl  
FT3 : 1.5 to 4.1 pg/ml  
FT4 : 0.8 to 1.90 ng/dl 
T4 : 4.5 to 12.5 μg/dl 
TSH : 0.42 to 5mIU/ml 
rT3 : 0.09 to 0.35 μg/ml 
 
 
 
 RESULTS AND ANALYSIS 
The present study titled “Thyroid profile in Acute coronary 
syndrome” was undertaken in the Department of Medicine and the 
Department of Cardiology, kilpauk medical college and hospital (Chennai) 
over a period of 12  months from November  2010  to October 2011. 
I) Prevalence of Sick Euthyroid Syndrome in ACS : 
SES No. of cases % of cases Cumulative % 
No 
Yes 
116 
39 
74.8 
25.2 
74.8 
25.2 
Total 155 100.0  
 
 
 
 
75% 
25% 
SES/ NORMAL THYROID PROFILE GROUP 
No Yes
 The above table shows 25.2% (39/155) of  patients with Acute 
Coronary Syndrome  had Sick Euthyroid State. Remaining 74.8% (116/155) 
of ACS patients had normal thyroid profile.                      
II) Prevalence of Sick Euthyroid State in various Type of ACS  
 
Type of ACS 
 
 
Patients 
with SES 
Patients 
with 
normal Thy 
Profile 
Total 
NSTEMI Count 8 35 43 
 % within Type of ACS 18.6% 81.4% 100% 
 % within Group 20.5% 30.2% 27.7% 
STEMI – AS Count 3 6 9 
 % within Type of ACS 33.3% 66.7% 100% 
 % within Group 7.7% 5.2% 5.8% 
STEMI- 
Ext.AW 
Count 12 23 35 
 % within Type of ACS 34.3% 65.7% 100% 
 % within Group 30.8% 19.8% 22.6% 
STEMI – IW Count 8 23 31 
 % within Type of ACS 25.8% 74.2% 100% 
 % within Group 20.5% 19.8% 20.0% 
UA - Count 8 29 37 
 % within Type of ACS 21.6% 78.4% 100% 
 % within Group 20.5% 25.0% 23.9% 
Total Count 39 116 155 
 % within Type of ACS 25.2% 74.8% 100% 
 % within Group 100% 100% 100% 
  
 
This pie diagram showed, 
21.6% (8/37) of patients with Unstable angina had SES;  
25.8% (8/31) of patients with STEMI IWMI had SES; 
34.3% (12/35) of patients with STEMI ASMI had SES; 
33.3% (3/9) of patients with Ext. AWMI had SES; 
18.6% (8/43) of patients with NSTEMI had SES. 
 
When these values were analyzed with statistical test, there was no 
significant difference of occurrence of SES with different type of ACS. 
Hence, the occurrence of SES did not influenced by the type of ACS.   
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65.7% 
74.2% 
78.4% 
Group B: Patients with Normal TP Group A: Patients with SES
Chi-Square Tests
3.101 4 .541
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 (II)  Distribution of Sick Euthyroid Syndrome in ACS patients and  
Comparison study between Group A (ACS patients with SES) & 
Group B (ACS patients without SES) : 
1)  According to age: 
 
 
 
     
 
 
Age * Group Crosstabulation
6 12 18
33.3% 66.7% 100.0%
15.4% 10.3% 11.6%
26 65 91
28.6% 71.4% 100.0%
66.7% 56.0% 58.7%
7 39 46
15.2% 84.8% 100.0%
17.9% 33.6% 29.7%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within Age
% within Group
Count
% within Age
% within Group
Count
% within Age
% within Group
Count
% within Age
% within Group
<= 40
41 - 60
> 60
Age
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
 This chart showed, 
33.3% (6/18) of  SES patients were less than 40 years of age; 
28.6% (26/91) of SES patients were in between 41 and 60 years of age; 
15.2% (7/46) of SES patients were more than 60 years of age.  
 
When statistical test was applied, there was no significant difference in 
the occurrence of SES among different ages. But if we applied the statistical 
analysis for each age group it was found that there was significant difference 
in the age group of  >60 yrs. The inference is that the occurrence of SES in 
old age is very less compared to other age groups.  
 
 
 
 
 
 
Chi-Square Tests
3.616 2 .164
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 SEX * Group Crosstabulation
15 41 56
26.8% 73.2% 100.0%
38.5% 35.3% 36.1%
24 75 99
24.2% 75.8% 100.0%
61.5% 64.7% 63.9%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within SEX
% within Group
Count
% within SEX
% within Group
Count
% within SEX
% within Group
Female
Male
SEX
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
2)  According to sex: 
                
                 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
P value was > 0.01 i.e.  insignificant, the inference is that the occurrence of 
SES  not influenced by sex. 
Chi-Square Tests
.123 1 .726
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 3)  According to BMI: 
 
   
 
This bar diagram showed, 
57.1% of SES patients were obese { BMI of  >27.5} 
21.4% of SES patients were overweight { BMI of 23.0 – 27.4 } 
16.7% of SES patients had normal { BMI 18.5- 22.9} 
Body Mass Index * Group Crosstabulation
1 1 2
50.0% 50.0% 100.0%
2.6% .9% 1.3%
8 40 48
16.7% 83.3% 100.0%
20.5% 34.5% 31.0%
18 66 84
21.4% 78.6% 100.0%
46.2% 56.9% 54.2%
12 9 21
57.1% 42.9% 100.0%
30.8% 7.8% 13.5%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within Body Mass Index
% within Group
Count
% within Body Mass Index
% within Group
Count
% within Body Mass Index
% within Group
Count
% within Body Mass Index
% within Group
Count
% within Body Mass Index
% within Group
< 18.5
18.5 - 22.9
23 - 27.4
> 27.5
Body
Mass
Index
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
50.0% 
16.7% 21.4% 
57.1% 
50.0% 
83.3% 78.6% 
42.9% 
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
<18.5 18.5-22.9 23-27.4 >27.5
BMI across SES/Normal TP 
Group B: Patients with
Normal TP
Group A: Patients with SES
  
The statistical analysis showed a significant association between the 
occurrence of SES and High BMI i.e. > 27.5 kg/m2 
4)  According to Diabetic state: 
             
29.5% of diabetics had SES; 18.3% of non diabetics had SES;      It was found 
that this association was statistically not significant. 
Chi-Square Tests
14.523 3 .002
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
Diabetics  * Group Crosstabulation
11 49 60
18.3% 81.7% 100.0%
28.2% 42.2% 38.7%
28 67 95
29.5% 70.5% 100.0%
71.8% 57.8% 61.3%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within Diabetics
% within Group
Count
% within Diabetics
% within Group
Count
% within Diabetics
% within Group
No
Yes
Diabet ics
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
Chi-Square Tests
2.424 1 .120
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 5)  According to Hypertension: 
 
 
 
 
25.5% of Hypertensive patients had SES and 25.0% of normotensive 
patients  had SES . This was statistically not significant.  
Hypertension * Group Crosstabulation
14 41 55
25.5% 74.5% 100.0%
35.9% 35.3% 35.5%
25 75 100
25.0% 75.0% 100.0%
64.1% 64.7% 64.5%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within Hypertension
% within Group
Count
% within Hypertension
% within Group
Count
% within Hypertension
% within Group
No
Yes
Hypertension
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
Chi-Square Tests
.004 1 .950
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 Dyslipidemia * Group Crosstabulation
16 65 81
19.8% 80.2% 100.0%
41.0% 56.0% 52.3%
23 51 74
31.1% 68.9% 100.0%
59.0% 44.0% 47.7%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within Dy slipidemia
% within Group
Count
% within Dy slipidemia
% within Group
Count
% within Dy slipidemia
% within Group
No
Yes
Dyslipidemia
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
6)  According to Dyslipidemia: 
 
 
 
 
 
 
 
 
 
31.1% of patients with dyslipidemia had SES when compared to 19.8% 
in case  of patients with normal lipid profile. This association was statistically 
not  significant. 
 
Chi-Square Tests
2.635 1 .105
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 7)  According to smoking habit: 
 
 
 
30.4% of smokers had SES when compared to 20.9% in non smokers.  
P value was >0.01, hence the smoking habit did not influence the prevalence  
of SES.  
Smoking * Group Crosstabulation
18 68 86
20.9% 79.1% 100.0%
46.2% 58.6% 55.5%
21 48 69
30.4% 69.6% 100.0%
53.8% 41.4% 44.5%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within Smoking
% within Group
Count
% within Smoking
% within Group
Count
% within Smoking
% within Group
No
Yes
Smoking
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
Chi-Square Tests
1.837 1 .175
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 8)  According to CRP: 
 
 
 
42.6% of  CRP positive ACS patients had SES but only 17.6% of CRP 
negative  individuals had SES. This was proved  statistically as significant.  
 
CRP Status * Group Crosstabulation
19 89 108
17.6% 82.4% 100.0%
48.7% 76.7% 69.7%
20 27 47
42.6% 57.4% 100.0%
51.3% 23.3% 30.3%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within CRP Status
% within Group
Count
% within CRP Status
% within Group
Count
% within CRP Status
% within Group
CRP Negative
CRP Positive
CRP Status
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
Chi-Square Tests
10.835 1 .001
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
 Chi-Square Tests
14.048 1 .002
155
Pearson Chi-Square
N of  Valid Cases
Value df P-v alue
9)  According to outcome: 
 
 
 
 
Nine out of 155 patients died.  21.9% of improved patients had SES 
where as 77.8% of patients who expired had SES. This was statistically 
significant. Hence it is concluded that SES was associated with worst 
outcome.   
Outcome * Group Crosstabulation
7 2 9
77.8% 22.2% 100.0%
17.9% 1.7% 5.8%
32 114 146
21.9% 78.1% 100.0%
82.1% 98.3% 94.2%
39 116 155
25.2% 74.8% 100.0%
100.0% 100.0% 100.0%
Count
% within Outcome
% within Group
Count
% within Outcome
% within Group
Count
% within Outcome
% within Group
Expired
Improv ed
Outcome
Total
Group A:
Patients
with SES
Group B:
Patients with
normal TP
Group
Total
 Group Statistics
146 77.6233 13.18313 1.09104
9 52.4444 17.37895 5.79298
Outcome
Improv ed
Expired
T3
N Mean Std.  Dev iat ion
Std.  Error
Mean
Independent Samples Test
5.457 153 .000 25.1788 4.61431 16.06286 34.29483T3
t df P-value
Mean
Dif f erence
Std.  Error
Dif f erence Lower Upper
95% Conf idence
Interv al of  the
Dif f erence
t-test  for Equality  of  Means
III)  Study of correlation between the thyroid profile and the outcome 
among the SES patients with Acute Coronary Syndrome: 
 
1) Correlation between T3 value and outcome: 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
The mean Total T3 value for the patient who were improved during 
hospital  stay was 77.62 ( normal limit 70- 100 microgram/dl);  where as the 
expired patients had very low mean i.e. 52.4. This was a statistically 
significant correlation. 
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 2)  Correlation between FT3 value and outcome: 
 
            
    
         
2.79 pg/ml was the mean value for the patients who were improved ; 
the expired patients had 2.65 pg/ml , but the difference was statistically not 
significant. 
Group Statistics
146 2.7917 .56384 .04666
9 2.6556 .70211 .23404
Outcome
Improv ed
Expired
FT3
N Mean Std.  Dev iation
Std.  Error
Mean
2.79 
2.65 
2.5
2.6
2.7
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2.9
Improved Expired
Mean FT3 across Outcome 
Independent Samples Test
.693 153 .489 .1362 .19642 -.25189 .52421FT3
t df P-value
Mean
Dif f erence
Std.  Error
Dif f erence Lower Upper
95% Conf idence
Interv al of  the
Dif f erence
t-test  for Equality  of  Means
 3) Correlation between T4 value and outcome: 
 
   
 
Even though there was a difference in the mean values 6.85 & 6.82 
μg/dl for  the patients who were improved or progressed to death respectively, 
this  difference was not significant by statistical analysis.  
Group Statistics
146 6.8506 1.97725 .16364
9 6.8278 1.70747 .56916
Outcome
Improv ed
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t4
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.034 153 .973 .0228 .67457 -1.30983 1.35550t4
t df P-v alue
Mean
Dif f erence
Std.  Error
Dif f erence Lower Upper
95% Conf idence
Interv al of  the
Dif f erence
t-test  for Equality  of  Means
 4)  Correlation between FT4 value and outcome: 
 
  
1 
2.05 ng/dl was the mean FT4 of  improved patients and  for the expired 
patients it was 1.38  ng/dl ; the difference was not significant. 
 
Group Statistics
146 2.0525 7.50040 .62074
9 1.3844 .21743 .07248
Outcome
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FT4
N Mean Std.  Dev iation
Std.  Error
Mean
2.05 
1.38 
0
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1
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Improved Expired
Mean FT4 across Outcome 
Independent Samples Test
.266 153 .790 .6680 2.50785 -4.28646 5.62250FT4
t df P-value
Mean
Dif f erence
Std.  Error
Dif f erence Lower Upper
95% Conf idence
Interv al of  the
Dif f erence
t-test  for Equality  of  Means
 5)  Correlation between TSH value and outcome: 
Group N Mean 
Std. 
Deviation 
Std. Error 
Mean 
Group A Patient Improved 146 2.8833 .60750 .09728 
Group B patient Expired 9 2.8371 .58773 .05457 
        
 
 
2.88 μIU/ml was the mean TSH of improved patients and for the 
expired paitents it was 2.83 μIU/ml. The difference was not significant 
statistically. 
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TSH across Groups 
Improved Expired 
Independent Samples Test
.422 153 .674 .0463 .10971 -.17048 .26300TSH
t df P-value
Mean
Dif f erence
Std.  Error
Dif f erence Lower Upper
95% Conf idence
Interv al of  the
Dif f erence
t-test  for Equality  of  Means
 6)  Correlation between rT3 value and outcome: 
 
 
 
The mean rT3 value for the patients who were progressed to death or 
improved  were 0.64 and 0.33 respectively. There was an association between 
and the high rT3 values and worst outcome. 
Group Statistics
146 .3317 .13719 .01135
9 .6433 .14440 .04813
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 DISCUSSION: 
Acute Coronary Syndrome is one of the leading cause of mortality and 
morbidity both in India and in the worldwide.
2
 The thyroid hormonal changes 
could result in the functional derangement of the cellular metabolism and 
affecting almost all the organs including the heart. This study was carried out 
with the aim of assessing the prevalence of one of the thyroidal hormonal 
derangement happening during any acute illness, the Sick Euthyroid 
Syndrome in patients with Acute Coronary Syndrome
9
. This study also 
assessed the distribution of SES in ACS and the correlation between thyroid 
hormone profiles with the outcome. 
This study titled "Thyroid Profile in Acute coronary syndrome" was 
carried out in the Department of Medicine and in the Department of 
cardiology, kilpauk medical college and hospital (Chennai). 
It is a Cross sectional study and was conducted during the period of  
November 2010 to October 2011( 12 months). 
I )  The prevalence of Sick Euthyroid State in Acute Coronary 
Sndrome: 
In this study of 155 Acute coronary Syndrome patients, 39 patients i.e. 
25.2% (39/155)   had Sick Euthyroid State. Remaining 74.8% (116/155) of 
ACS  patients had normal thyroid profile. So the total  unadjusted prevalence 
of SES in ACS patients is 25.2% .    
 This observation is similar to  Ramsden DB
53
, et al  who reported the 
prevalence of SES in acute infarction was 22.7% 
The prevalence of SES in different type of ACS as follows: 
21.6% (8/37) of patients with Unstable angina had SES; 25.8% (8/31) 
of patients with STEMI IWMI had SES; 34.3% (12/35) of patients with 
STEMI ASMI had SES; 33.3% (3/9) of patients with Ext. AWMI had SES; 
18.6% (8/43) of patients with NSTEMI had SES. 
When we compared with the non SES group this prevalence rate not 
significant. Hence, the prevalence of  SES in different type of ACS is same. 
This observation is similar to Rodrigo Caetano Pimentel et al.
54
  who 
reported that equal prevalence of SES in various types of ACS But Franklin 
JA et al reported that the incidence of SES was common after a myocardial 
infarction than Unstable Angina. This may be because of case selection in that 
study; He selected cases without matching the known confounding factors 
like systemic inflammatory conditions. 
(III) Distribution of Sick Euthyroid Syndrome in ACS patients and 
Comparison study between Group A (ACS patients with SES) & Group 
B  (ACS patients without SES) : 
Age distribution of SES: 
In this study,  33.3% (6/18) of  SES patients were less than 40 years of 
age; 28.6% (26/91) of SES patients were in between 41 and 60 years of age; 
15.2% (7/46) of SES patients were more than 60 years of age. The prevalence 
 of SES were equal in the first two groups but in case of older age group it was 
lesser. So, older age individuals are less vulnerable to develop SES. Even 
though there was significant difference in prevalence of SES between old age 
and younger age, the other confounding factors such as BMI to be considered. 
Because in our study, the mean BMI of old age patients was very less 
compared to younger age group. But the BMI was the strong predictor of SES 
in our study. This partially explained the low prevalence of SES in old age.    
Wiersinga WA et al. reported in his study that the equal distribution of 
SES cases in all age group. But in our study we could not match the known 
confounding factors because of small number of cases. This explained why 
the old age people had lower incidence of SES.
58
 
According to sex: 
26.8% of females had SES and 24.5% of male patients had SES. P 
value was > 0.05 i.e.  insignificant, the inference is that the occurrence of SES 
not influenced  by sex. 
 Luiz Maurino et al. from Brazil reported that the incidence of SES 
after myocardial infarction was similar in both males and females. This is 
very similar to our study.
61
 
According to BMI: 
 In the present study, 57.1% of SES patients were obese { BMI of  
>27.5} 21.4% of SES patients were overweight { BMI of 23.0 – 27.4 } 16.7% 
of SES patients had normal { BMI 18.5- 22.9}. 
This also showed that 50% of people had BMI of  < 18.5; but this 
should not be considered because only 2 patients were underweight . So, this 
will affect the over all statistical significance. 
The statistical analysis showed the P value of 0.002 i.e., a significant 
association between the prevalence of SES and High BMI i.e. > 27.5 kg/m2. 
         There are several studies to support our observation in this study. 
Examples include Kliridis PA et al. reported the statistically significant effect 
of BMI in the incidence of SES after acute ischemic syndrome.
73
  
According to Diabetic state: 
29.5% of diabetics had SES; 18.3% of non diabetics had SES. The P 
value was 0.120 
69
; hence  the association between diabetic state and 
prevalence of SES was statistically not significant. 
This is similar to the observation of Langster W, et al from 
Philadelphia. He reported that statistically insignificant effect of diabetics in 
the incidence of SES after a MI
65
. 
 According to Hypertension: 
25.5% of Hypertensive patients had SES and 25.0% of normotensive 
patients had SES. Both the hypertensive patients and normotensives had the 
equal prevalence of SES. This was proved by statistical analysis. 
Burman KD  et al. reported the similar observation.
78
 
According to Dyslipidemia: 
31.1% of patients with dyslipidemia had SES when compared to 19.8% 
in case of patients with normal lipid profile. This association was statistically 
not significant. 
This is similar to the report of  Kanda T, et al. who stated in his study 
that statistically insignificant effect of dyslipidemia in the occurrence of SES 
in MI.
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According to smoking habit: 
30.4% of smokers had SES when compared to 20.9% in non smokers.  
P value was >0.01, hence the smoking habit did not influence the 
prevalence of SES.  
 Kotajima N, et al., reported that smoking did not affect the incidence 
of SES in ACS after matching the known confounding factors. This is similar 
to our study
67
. 
According to CRP: 
42.6% of  CRP positive ACS patients had SES but only 17.6% of CRP 
negative individuals had SES.  There was a strong association between CRP 
status and the prevalence of SES. This was proved  statistically as significant.  
P value  0.001.  
Larsen PR et al. reported that incidence of SES after MI was 4 times 
greater in CRP positive group when compared to CRP negative group. In our 
study we reported that three times the risk of developing SES after MI
71
. 
According to outcome: 
 In this study nine out of one hundred and fifty five patients died.  Out 
of the nine, seven patients had SES when compared with two patients in the 
normal thyroid profile group. The P value was  0.002 , significant; Hence it is 
concluded that SES was  associated with worst outcome.   
 Escosteguy et al , one of the editors of The American Clinical 
Cardiology, reported in his study that the SES group of patients had worst 
outcome when compared to patients with normal thyroid profile
73
. 
 III) Study of correlation between the thyroid profile and the outcome 
among the SES patients with Acute Coronary Syndrome: 
1) Correlation between T3 value and outcome: 
The mean Total T3 value for the patient who were improved during 
hospital stay was 77.62 ( normal limit 70- 100 microgram/dl); where as the 
expired patients had very  low mean i.e. 52.4. This was a statistically 
significant correlation. hence low total T3 level associated with worst 
outcome. 
Michele Coceani, MD et al reported in his article named ‗Thyroid 
Hormone and Coronary Artery Disease: From Clinical Correlations to 
Prognostic Implications‘ that low T 3 level positively correlated with the 
prognosis both for short term and long term. Barison A, et al. also reported 
the similar correlation. This is similar to our study observation.
70
 
2. Correlation between FT3 value and outcome: 
2.79 pg/ml was the mean value for the patients who were improved ; 
the expired patients had 2.65 pg/ml , but the difference was statistically not 
significant. So, FT3 value neither changed nor affecting the prognosis in SES. 
Wartofsky et al reported the similar observation. 
  
3. Correlation between T4 value and outcome: 
Even though there was a difference in the mean values 6.85 & 6.82 
ng/dl for the patients who were improved or progressed to death respectively, 
this difference was not significant by statistical analysis. T4 value was not 
changed in our study. 
Kotajima N, et al reported T4 value may get reduced in severe cases
78
 
4. Correlation between FT4 value and outcome: 
2.05 ng/dl was the mean FT4 of  improved patients and  for the expired 
patients it was 1.38  n g/dl ; the difference was not significant. Hence the FT4 
value will remain same in both worst out come group and better outcome 
group. 
Yamada E, et al reported similar observation 
5. Correlation between TSH value and outcome: 
 2.88 μIU/ml was the mean TSH of improved patients and for the 
expired paitents it was 2.83 μIU/ml. The difference was not significant 
statistically. Hence the TSH value will remain same in both worst out come 
group and better outcome group.
70 
Tauber JL. et al reported that in case of very sick condition T4 also reduced; 
but the TSH should be within normal limits
75
 
 
 6. Correlation between rT3 value and outcome: 
The mean rT3 value for the patients who were progressed to death or 
improved  were 0.64 and 0.33 respectively. There was an association 
between and the high  rT3 values and worst outcome. 
Utiger RD.et al reported that the rT3 is well correlated with high 
mortality 
71
 
This is similar to our observation. 
 
 
 
 
 
 
 
 
 
 SUMMARY: 
This study aimed at estimating the prevalence of sick euthroid state in 
patients  with ACS and also to find out its correlation with various risk factors 
for CAD. Finally to study the correlation of thyroid hormone profiles with 
outcome. 
The study sample included 155 ACS patients admitted in ICCU and in 
the Medical wards. Each patient was assessed clinically and by laboratory 
investigations. 
Primary observations regarding Sick Euthyroid State in patients with 
Acute Coronary Syndrome: 
 The above table shows 25.2% (39/155) of  
patients with Acute Coronary Syndrome  had Sick Euthyroid State.  
 Sick Euthyroid state occurs in all type of ACS with equal proportion , 
even though there were statistically insignificant variation. 
 Sick Euthyroid state occurs in all age group and low prevalence of this 
condition noted in old age group. 
 Sick Euthyroid state significantly associated with High BMI, CRP 
positivity and this condition associated with worst outcome.  
  Sick Euthyroid state did not significantly correlated with sex, diabetic 
state, hypertension, dyslipidemia and smoking. 
 The T3 value well correlated with outcome i.e. low T3 associated 
worst outcome among SES patients. 
 The rT3 value also well correlated with outcome i.e. high rT3 
associated worst outcome among SES patients. 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION: 
Prevalence of Sick Euthyroid State is very common in patients with 
Acute Coronary Syndrome. Almost one quarter of ACS patients had SES.       
P      Prevalence of SES   in old age group is low as compared to younger 
population.   
Sick Euthyroid state significantly associated with High BMI, CRP 
positivity and this condition associated with worst outcome. So SES is a 
strong prognostic indicator in acute coronary syndrome.  
Sick Euthyroid state did not significantly correlated with sex, diabetic 
state, hypertension, dyslipidemia and smoking. 
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 Study of Thyroid Profile in Acute Coronary Syndrome: 
Pro forma: 
Name of the Patient : 
Age:                                                                                DOA: 
Sex:                                                                                 DOD: 
Occupation:                                                              
Socioeconomic status: 
Address: 
 
CLINICAL PROFILE: 
Presenting complaints: 
 
 
H/O Past illness: 
 
 
General Examination: 
Pallor                  Cyanosis                   Clubbing                     Icterus                      JVP    
Thyroid swelling                           Lymphadenopathy                    Pedal edema 
 
 
Vitals: 
Pulse 
BP 
RR 
  
 
 
 
Systemic examination: 
CVS 
RS                                                              P/A 
CNS 
ECG:  
 
DIGNOSIS: 
 
Risk factors: 
 
Killips class: 
TIMI Score: 
 
 
 
BIOCHEMICAL PROFILE: 
Complete Blood Count; 
      TC                               DC           Hb%                       ESR 
Urine Examination; 
     Sugar                         Albumin                            Deposit 
Blood sugar  
          RBS 
         FBS 
        PPBS 
Blood Urea 
Serum Creatinine 
Serum Electrolytes 
              Na                   K 
 
Fasting Lipid profile 
     T Chol. 
     TGL 
CPK MB 
 
                                          
Fasting Thyroid profile:        At 3rd  day  of admission                 
     Free T3 
     Free T4 
     rT3 
     TSH 
     T3 
      T4 
 
 
 
IMAGING PROFILE: 
 Chest X ray 
Echocardiography 
      
 
Course during In Hospital stay: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NAME AGE SEX  BMI DM  SHT DYSLIPD SMOKING TYPE OF ACS CRP   ECHOCARDIOGRAM                                               THYROID PROFILE         OUTCOME
Kg/m2 RWMA            EF% LV Fn T3(μg/dl)  FT3(pg/ml)  rT3(μg/dl)   T4(μg/dl)    FT4(μg/dl)    TSH(mU/ml) INFERENCE
Rajan 55 M 24.34 Yes Yes No Yes STEMI - AS P  IVS , IV apex      35%  Severe    47          2.87              0.57          9.64         1.43            3.57               SES Improved
Krishnan 63 M 21.22 Yes No No Yes STEMI - IW N Lower IVS Inf wall 41% Mod    78          2.7               0.13          7.83          1.71            2.83            Normal Improved
Kasiammal 67 F 19.84 No Yes Yes No STEMI- IW N  Inf wall        49%   Mild    97          3.11             0.21          11.68         1.27            1.63            N Improved
Varatha rajan 60 M 26.8 No Yes Yes Yes NSTEMI P No RWMA     63% Normal    63          3.87             0.43          8.09           1.49           2.87              SES Improved
Swaminathan 45 M 25.06 Yes No Yes No STEMI- AS N IV apex, ant wall 33%  Severe    87          2.76             0.23          7.86          1.09             3.51              N Improved
Zuleka bee 80 F 26.56 Yes Yes Yes No UA - CL III N No RWMA      67% Normal    79          3.67             0.19          8.93          0.98            3.70               N Improved
Kesavan 62 M 27.68 Yes Yes Yes No STEMI- AS P IVS, Lat wall    47% Mod     57          1.89           0.63           5.65         0.97             2.37                 SES Improved
Mohana sundaram 53 M 26.56 Yes Yes No No NSTEMI N No                 65% Normal    93          2.31             0.13          4.87           1.31           3.42                N Improved
Kuttiammal 60 F 17.66 No Yes No No UA - CL III N No                 68% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Selvaraj 52 M 22.34 No Yes No Yes UA - CL III N No                 60% Normal    51          2.97             0.53          7.83           1.09           2.24             SES Improved
Elango 52 M 24.45 Yes No Yes Yes STEMI- AS N IVS , IV apex   37%  Severe     83          2.61              0.27         5.39          1.52            2.87                N Improved
Rajeswari 71 F 23.21 Yes Yes No No STEMI- IW P Lower IVS Inf wall 40% Mod     62          3.11             0.43           8.60          1.73           2.87              SES Improved
Sakunthala 70 F 24.64 No Yes Yes No UA - CL III N No                 63% Normal     93          2.61              0.25         5.31         1.59            3.87                N Improved
Egavalli 58 F 26.46 Yes Yes No No NSTEMI N LV apex     54%       mild      88          2.21              0.37         5.30          1.02            2.97                N Improved
Sekar 37 M 28.66 Yes No Yes Yes STEMI- Ext.AW N Ant&Lat wall  25%   severe     73          2.69              0.20         5.36          1.12            3.87                N Improved
Nirmal narendar 35 M 27.55 Yes Yes Yes Yes STEMI- Ext.AW P Global    25%   severe     33           2.12           0.78           4.60         1.56            0.76               SES Expired
Muniammal 70 F 22.86 Yes No No No UA - CL III N No                 68% Normal    73          3.81              0.37         4.99          1.56            2.77                N Improved
Rajendran 39 M 25.78 No Yes Yes Yes NSTEMI N No                 63% Normal    89          2.90              0.17         7.30          1.02            1.87                N Improved
Kannappan 36 M 24.68 No Yes Yes Yes STEMI- AS N IVS , IV apex    30%  Severe    93         2.61              0.21         7.39          0.92            2.87                N Improved
Dass 45 M 25.64 Yes Yes No Yes NSTEMI P LV apex   55%    Adequate     83          3.67              0.30         6.09          1.52            2.50                N Improved
Gopalakishnan 60 M 26.66 Yes No No Yes UA - CL III N No                 63% Normal    72          3.78              0.37         5.39          1.92            3.87                N Improved
Thirugnana sundari 56 F 24.65 No Yes Yes No NSTEMI N No                 63% Normal    80          3.03             0.26          6.47          1.06            2.87              Normal Improved
Balaji 43 M 27.88 Yes Yes Yes Yes STEMI- AS P IVS , IV apex      37%  Severe     41         3.38            0.79           7.35          1.25           2.39               SES Expired
Iqbal 46 M 28.82 Yes Yes Yes No STEMI- IW P Lower IVS Inf wall 48% Mod    57          1.89             0.51          6.72           0.97           3.85              SES Improved
Ramu 43 M 26.44 Yes No No Yes NSTEMI N LV apex     54%       mild     79          3.67              0.09         10.33          2.57            0.77                N Improved
Rathika 63 F 19.9 No Yes No No UA - CL III N No                 63% Normal    69          4.01              0.37         8.39          1.50            3.89                N Improved
Panchammal 59 F 24.42 Yes Yes No No STEMI- IW P Lower IVS Inf wall 48% Mod    83          2.61              0.25         5.39          1.72            2.27                N Improved
Kandasamy 55 M 20.04 No Yes No No NSTEMI N No                 63% Normal    87          3.51              0.30         8.79          092            2.87                N Improved
Jameela 75 F 26.68 Yes Yes Yes No STEMI- IW N Lower IVS Inf wall 48% Mod    80          2.89             0.27         5.35          1.07            2.86                N Improved
  
Luisraj 50 M 23.42 Yes No No No UA - CL III N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Jaya 69 F 19.84 Yes Yes No No UA - CL III N No                 63% Normal    54          3.33              0.47          4.49          1.02           2.56               SES Improved
Govindaraj 47 M 25.66 Yes Yes No Yes STEMI- AS N IVS , IV apex      37%  Severe    83          3.61              0.23         6.39          1.42           3.07                N Improved
Subha rao 30 M 28.48 Yes Yes Yes Yes STEMI- Ext.AW P Global    25%   severe     51          2.76             0.68          4.98           1.22           0.49               SES Expired
Durai raj 63 M 24.44 Yes No No Yes UA - CL III N No                 70% Normal    90          2.61              0.31         5.81          1.70            2.07                N Improved
Sowbakiyam 65 M 20.88 No Yes No No NSTEMI N No                 60% Normal    93          2.60              0.17         5.39          1.52            2.87                N Improved
Kuppan 55 M 22.38 No Yes Yes No NSTEMI N No                 63% Normal    79          3.31              0.31         5.84          1.28            3.48                N Improved
Kubendran 52 M 24.22 No Yes Yes Yes STEMI- IW P Lower IVS Inf wall 48% Mild    91          1.89              0.19        7.48          1.07            3.87                N Improved
Shankari 45 F 25.06 Yes No No Yes STEMI- AS P IVS , IV apex      37%  Mod    59           1.89            0.43           4.93         1.72           2.87               SES Improved
kumari 60 F 26.68 Yes Yes Yes No STEMI- AS N IVS , IV apex      37%  Mod    80          2.61              0.27         10.39          1.52            2.07                N Improved
Abdul majeed 40 M 26.44 Yes Yes No No UA - CL III N No                 65% Normal    76          2.71              0.48         7.69          1.52            2.09                N Improved
Stalin 42 M 23.48 No Yes Yes Yes NSTEMI P No                 63% Normal    83          2.73              0.27         7.30          1.52            2.07                N Improved
Muniyappan 43 M 26.14 No Yes Yes Yes NSTEMI N LV apex     54%   adequate     60          2.65             0.49          7.53          1.03            3.38              SES Improved
Subhuraj 60 M 24.9 Yes No No Yes STEMI- AS N IVS , IV apex  39%  Mod    83          2.61              0.37         5.39          1.50            2.82               N Expired
Ponnammal 52 F 19.98 Yes No No No STEMI- IW N Lower IVS Inf wall 48% Mild    53           3.05            0.51          6.98           1.28           1.04             SES Improved
Sivakumar 40 M 24.04 No Yes No Yes UA - CL III N No                 70% Normal    99          3.61              0.27         5.39          1.52            2.87                N Improved
Kandasamy 52 M 22.56 No Yes No Yes NSTEMI P No                 63% Normal    73          2.91              0.20         7.39          0.92            2.09                N Improved
Usha 47 F 27.84 Yes Yes Yes No STEMI- AS N IVS , IV apex      37% Mod    49           3.73            0.61          7.51         1.73            0.57             SES Expired
Krishnan 65 M 23.9 No Yes No No UA - CL III N No                 63% Normal    83          2.82             0.27         9.39          1.52            2.87                N Improved
Soundaram 65 F 24.48 Yes Yes Yes No STEMI- IW N Lower IVS Inf wall 48% Mild    93          2.61              0.27         5.39          1.59            2.87                N Improved
Rajammal 74 F 19.24 No Yes No No UA - CL III N No                 67% Normal    83          3.67              0.29        5.07          1.91            2.38                N Improved
Palani 40 M 27.88 Yes Yes No Yes STEMI- AS P IVS , IV apex      30%  Severe    83          1.89              0.35         11.89         1.27            3.28                N Improved
Gnanasekar 48 M 26.68 Yes No Yes Yes STEMI- IW N Lower IVS Inf wall 48% Mild    61          3.71             0.43           8.04          1.41         0.93                SES Improved
Padmavathy 57 F 20.08 No Yes No No NSTEMI N LV apex     54%       adeq     83          2.61              0.27         5.39          1.52            2.07                N Improved
Sakthivel 24 M 28.42 Yes Yes Yes Yes STEMI- Ext.AW P Global    25%   severe   80          2.61              0.31         8.24          1.70            2.87                N Improved
Selvakumar 39 M 24.78 Yes Yes Yes Yes STEMI- AS P IVS , IV apex  37%  Mod    83          2.61              0.27         5.39          1.52            2.87                N Improved
Rajathi 45 F 23.64 Yes No No No UA - CL III N No                 62% Normal    54          1.68              0.49         7.83          0.85            4.02              SES Improved
Rangasamy 55 M 22.86 No No Yes No NSTEMI N No                 63% Normal    66          2.41             0.49           4.90          1.09           2.89               SES Improved
Sakunthala 67 F 24.82 Yes No Yes No STEMI- IW N Lower IVS  50% adequate    91          1.89              0.30         8.21          1.34            3.28                N Improved
Ganapathy 35 M 25.06 No Yes Yes Yes STEMI- IW N Lower IVS Inf wall 48% Mild    98          2.61              0.34         5.39          1.07            2.80                N Improved
Harikrishnan 54 M 23.82 No No Yes Yes NSTEMI N LV apex     54%   adequate     83          2.67              0.27         7.82          1.52            2.87                N Improved
Punitha 58 F 24.64 Yes No No No UA - CL III N No                 63% Normal    72          4.0              0.32         5.39          0.97             3.78                N Improved
Devendran 47 M 25.68 Yes Yes No Yes STEMI- IW P Lower IVS Inf wall 48% Mild    83          2.61              0.27         5.39          1.24            1.89                N Improved
Natarajan 60 M 23.64 No Yes No No NSTEMI N LV apex     54%  Adequate     57          3.57             0.60          11.03        1.78             0.43             SES   Improved
Selvaraj 49 M 26.82 Yes No Yes Yes STEMI- AS N IVS , IV apex      37%  Mod    83          2.61              0.27         5.39          1.52            2.87                N Improved
Abdullah 49 M 25.66 Yes No No No STEMI- IW N Lower IVS Inf wall 48% Mild    69          3.84             0.30         11.25          1.70           3.99                N Improved
  
Abdullah 49 M 25.66 Yes No No No STEMI- IW N Lower IVS Inf wall 48% Mild    69          3.84             0.30         11.25          1.70           3.99                N Improved
Arumugam 30 M 27.84 Yes No Yes Yes STEMI- AS P IVS , IV apex      37%  Mod    59           3.42            0.63          6.72          1.27            0.57              SES Improved
Nazeemunnisa 60 F 26.86 Yes No Yes No NSTEMI N No                 65% Normal   93          2.48              0.27         5.39           1.50            2.89                N Improved
Velankanni 45 F 24.48 Yes Yes No No UA - CL III N No                 63% Normal    79          1.99              0.31         10.84          1.09            2.87                N Improved
Kuppan 39 M 24.82 No Yes Yes Yes STEMI- AS P IVS , IV apex      47%  Mild   83          2.61              0.27         5.39          1.52            2.87                N Improved
Sivasankari 44 F 23.44 Yes No No No STEMI- IW N Lower IVS Inf wall 48% Mild    37          2.87             0.79          10.15         1.01          0.92                SES Expired
Kesavan 45 M 26.22 Yes Yes No Yes STEMI- AS N IVS , IV apex   38%  Mod    83          2.61              0.27         5.39          1.52            4.09                N Improved
Suseela 55 F 19.9 No Yes Yes No UA - CL III N No                 60% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Jayachandran 50 M 21.24 No Yes No Yes UA - CL III N No                 67% Normal    49          3.51              0.63          7.21         1.82            0.57               SES Improved
Sampantham 58 M 24.84 Yes No No No NSTEMI N No                 63% Normal    83          1.95              0.27         6.89          0.96            2.87                N Improved
Jothi 48 F 27.57 Yes Yes Yes No STEMI- AS N IVS , IV apex  39%  Mod    103          2.61              0.27         5.39          1.52            3.02                N Improved
Indrani 60 F 20.08 No Yes No No NSTEMI N No                 63% Normal    53          2.09             0.58         7.29           1.26            3.04              SES Improved
Radha 49 F 23.57 Yes Yes No No NSTEMI N No                 64% Normal    91          2.61              0.27         5.39          1.52            2.87                N Improved
Hendry 49 M 23.53 No No Yes Yes UA - CL III P No                 69% Normal    83          2.40             0.32         5.39          1.78            3.05                N Improved
Balu 44 M 27.37 Yes Yes Yes Yes STEMI- AS N IVS , IV apex   42% Mod    94          2.61              0.27         10.90          1.52            3.41                N Improved
Sekar 47 M 25.95 Yes No Yes Yes STEMI- Ext.AW P Global    25%   severe    57         1.34             0.67            5.43             1.72            2.30            SES Improved
Venkatesan 45 M 26.44 Yes Yes No Yes STEMI- AS N Ant wall, IV apex  35%  Severe    83          2.61              0.27         5.39          1.52            2.87                N Improved
Chandrasekar 46 M 22.87 No Yes No Yes NSTEMI N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Ganesamoorthy 40 M 28.45 Yes No Yes Yes STEMI- AS P IVS , IV apex  39%  Mod    49         2.43             0.57           6.47            1.37           1.89            SES  Improved
Nirmala 44 F 21.09 No Yes No No UA - CL III N No                 60% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Elumalai 55 M 22.66 Yes No No No STEMI- IW N Lower IVS Inf wall 38% Mod    92          2.61              0.34         11.09          1.76            3.21                N Improved
Saroja 70 F 21.83 No Yes No No UA - CL III N No                 60% Normal     59         2.65             0.61          5.30          1.00            2.31              SES Improved
Mohammada bee 58 F 24.48 Yes No Yes No NSTEMI N No                 63% Normal    78          3.61              0.32         8.39          1.57            2.07                N Improved
Padmanaban 67 M 26.33 Yes No Yes No NSTEMI N No                 68% Normal    90          2.61              0.37         12.04          1.70            3.41                N Improved
Samikannu 60 M 22.64 No No Yes No STEMI- IW P Lower IVS Inf wall 48% Mild    86          2.69              0.20         8.97          1.52            2.83                N Improved
Venkatesan 31 M 28.54 Yes Yes Yes Yes STEMI- AS P IVS , IV apex 39%  Mod    42          1.76              0.72          5.31         0.92            0.97              SES Improved
Govindammal 75 F 19.42 No Yes No No UA - CL III N No                 65% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Muniammal 60 F 22.65 Yes Yes No No NSTEMI N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Shanmugam 49 M 26.55 Yes Yes Yes Yes STEMI- Ext.AW P Ant, Lat wall 35%   severe    83          2.61              0.27         5.39          1.52            2.87                N Improved
Mannu 49 M 22.89 No Yes No Yes NSTEMI P No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Govindasamy 65 M 21.87 No Yes Yes No STEMI- AS N IVS , IV apex      40% Mod    83          2.61              0.27         5.39          1.52            2.87                N Improved
Velu 38 M 27.65 Yes Yes Yes Yes STEMI- AS N IVS , IV apex      30%  Severe    83          2.61              0.27         5.39          1.52            2.87                N Improved
Pavithra kumar 45 M 25.34 Yes No Yes Yes STEMI- IW N Lower IVS Inf wall 48% Mild    42          1.87             0.74          5.27           0.93           0.33              SES Improved
Kannathal 65 F 21.56 yes No No No STEMI- IW P  Inf wall    56%  adeq    83          2.61              0.27         5.39          1.52            2.87                N Improved
Settu 45 M 24.33 No Yes No Yes NSTEMI N No                 64% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
  
Hendry 49 M 23.53 No No Yes Yes UA - CL III P No                 69% Normal    83          2.40             0.32         5.39          1.78            3.05                N Improved
Balu 44 M 27.37 Yes Yes Yes Yes STEMI- AS N IVS , IV apex   42% Mod    94          2.61              0.27         10.90          1.52            3.41                N Improved
Sekar 47 M 25.95 Yes No Yes Yes STEMI- Ext.AW P Global    25%   severe    57         1.34             0.67            5.43             1.72            2.30            SES Improved
Venkatesan 45 M 26.44 Yes Yes No Yes STEMI- AS N Ant wall, IV apex  35%  Severe    83          2.61              0.27         5.39          1.52            2.87                N Improved
Chandrasekar 46 M 22.87 No Yes No Yes NSTEMI N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Ganesamoorthy 40 M 28.45 Yes No Yes Yes STEMI- AS P IVS , IV apex  39%  Mod    49         2.43             0.57           6.47            1.37           1.89            SES  Improved
Nirmala 44 F 21.09 No Yes No No UA - CL III N No                 60% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Elumalai 55 M 22.66 Yes No No No STEMI- IW N Lower IVS Inf wall 38% Mod    92          2.61              0.34         11.09          1.76            3.21                N Improved
Saroja 70 F 21.83 No Yes No No UA - CL III N No                 60% Normal     59         2.65             0.61          5.30          1.00            2.31              SES Improved
Mohammada bee 58 F 24.48 Yes No Yes No NSTEMI N No                 63% Normal    78          3.61              0.32         8.39          1.57            2.07                N Improved
Padmanaban 67 M 26.33 Yes No Yes No NSTEMI N No                 68% Normal    90          2.61              0.37         12.04          1.70            3.41                N Improved
Samikannu 60 M 22.64 No No Yes No STEMI- IW P Lower IVS Inf wall 48% Mild    86          2.69              0.20         8.97          1.52            2.83                N Improved
Venkatesan 31 M 28.54 Yes Yes Yes Yes STEMI- AS P IVS , IV apex 39%  Mod    42          1.76              0.72          5.31         0.92            0.97              SES Improved
Govindammal 75 F 19.42 No Yes No No UA - CL III N No                 65% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Muniammal 60 F 22.65 Yes Yes No No NSTEMI N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Shanmugam 49 M 26.55 Yes Yes Yes Yes STEMI- Ext.AW P Ant, Lat wall 35%   severe    83          2.61              0.27         5.39          1.52            2.87                N Improved
Mannu 49 M 22.89 No Yes No Yes NSTEMI P No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Govindasamy 65 M 21.87 No Yes Yes No STEMI- AS N IVS , IV apex      40% Mod    83          2.61              0.27         5.39          1.52            2.87                N Improved
Velu 38 M 27.65 Yes Yes Yes Yes STEMI- AS N IVS , IV apex      30%  Severe    83          2.61              0.27         5.39          1.52            2.87                N Improved
Pavithra kumar 45 M 25.34 Yes No Yes Yes STEMI- IW N Lower IVS Inf wall 48% Mild    42          1.87             0.74          5.27           0.93           0.33              SES Improved
Kannathal 65 F 21.56 yes No No No STEMI- IW P  Inf wall    56%  adeq    83          2.61              0.27         5.39          1.52            2.87                N Improved
Settu 45 M 24.33 No Yes No Yes NSTEMI N No                 64% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Saravanan 32 M 28.89 Yes Yes Yes Yes STEMI- AS P IVS , IV apex      37% Mod    42          2.43             0.67          6.47           1.28           3.89              SES Expired
  
Thirunavukkarasu 45 M 26.43 Yes No No Yes UA - CL III N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Dhandabani 45 M 28.54 Yes Yes Yes Yes STEMI- Ext.AW N Global    25%   severe    83          2.61              0.27         5.70          1.23            2.90                N Improved
Suresh 53 M 22.43 No Yes No No NSTEMI N LV apex     54%  adequate    83          2.61              0.27         5.39          1.52            2.87                N Improved
Gayathri 51 F 21.34 No Yes No No UA - CL III P No                 63% Normal    89          2.61              0.27         10.87          1.50           2.87                N Improved
Kumutha 67 F 22.45 No No Yes No UA - CL III N No                 53% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Santhosam 57 M 24.76 Yes Yes No Yes NSTEMI N LV apex     54%  Adequate     60          3.81             0.43          9.73           1.27           3.92               SES Improved
Rani 56 F 21.54 No Yes No No NSTEMI N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Joseph 63 M 26.54 Yes No Yes Yes STEMI- IW P Lower IVS Inf wall 48% Mild    54          2.87             0.69          6.27           1.37           2.83               SES Improved
Ramaiya 57 M 24.58 Yes No No No STEMI- IW N Lower IVS Inf wall 47% Mild    83          2.61              0.27         5.39          1.52            2.87                N Improved
Rajammal 78 F 19.08 No Yes No No UA - CL III N No                 62% Normal    80          2.61              0.37         5.39          1.75            2.87                N Improved
Kumaran 67 M 25.83 Yes No No Yes NSTEMI N No                 69% Normal    83         3.86              0.35         10.98          1.70            3.40                N Improved
Sarangapani 54 M 23.54 Yes No No Yes STEMI- IW P Lower IVS Inf wall 48% Mild    83          2.61              0.27         5.39          1.52            2.87                N Improved
Kokilammal 65 F 21.58 No Yes Yes No NSTEMI N No                 60% Normal   78          2.76              0.07         7.39          1.82            2.07                N Improved
Palaniyammal 69 F 19.98 No Yes Yes No UA - CL III P No                 63% Normal    61          3.67             0.49          8.63          1.09            3.30             SES   Improved
Rajasekar 49 M 25.61 Yes No No Yes STEMI- AS N IVS , IV apex      33%  Severe    87          2.11              0.36         12.65          1.70            3.87                N Improved
Moorthy 52 M 26.83 Yes Yes Yes No NSTEMI N LV apex     54%   Adequate     87          2.43              0.29         8.39          1.57            2.80                N Improved
Batcha 63 M 28.88 Yes Yes Yes No STEMI- IW N Lower IVS Inf wall 48% Mild    83          2.61              0.27         5.39          1.52            2.87                N Improved
Rangarajan 49 M 26.63 Yes Yes Yes No STEMI- AS P IVS , IV apex  33%  Severe    83          2.60              0.35         5.98          1.32            3.87                N Improved
Poongodi 54 F 24.48 Yes No Yes No UA - CL III N No                 67% Normal    59          3.87             0.50          7.43          1.41            2.59              SES Improved
Kathiravan 46 M 24.45 No Yes No Yes NSTEMI N No                 63% Normal    80          3.24              0.35         10.67          1.52            2.86                N Improved
Dharani 52 F 22.06 Yes No No No STEMI- IW P Lower IVS Inf wall 48% Mod    83          2.61              0.27         5.39          1.52            2.87                N Improved
Subbaiah 67 M 23.78 No Yes No Yes UA - CL III N No                 60% Normal    98          2.67              0.09         5.30          1.09           2.98                N Improved
Kaliammal 73 F 18.08 No Yes No No NSTEMI N LV apex     54%       mild     64          3.61             0.42          7.34          1.27            3.38               SES  Improved
Lakshmiammal 64 F 21.9 Yes No No No UA - CL III N No                 69% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Babu 39 M 26.87 Yes No Yes Yes STEMI- Ext.AW P Global    25%   severe    80          2.91              0.30         11.39          1.07            2.08                N Improved
Kamal basha 49 M 23.87 Yes No No Yes UA - CL III N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Murugan 57 M 21.76 No Yes Yes No NSTEMI N No                 67% Normal    97          3.85              0.37         7.39          1.54            2.07                N Improved
Rajammal 68 F 22.43 Yes No No No STEMI- IW N Lower IVS Inf wall 45% Mild    87          2.60              0.29         5.09          1.52            2.89                 N Improved
Murugeswari 49 F 26.89 Yes Yes Yes No STEMI- AS P IVS , IV apex      39%  Mod    49          3.85             0.79          6.34          1.63            0.97             SES Improved
Muthammal 53 F 20.65 No Yes Yes No NSTEMI N No                 70% Normal    83          2.61              0.20         5.98          1.09            2.87                N Improved
Kannan 43 M 26.45 No Yes No Yes NSTEMI N No                 66% Normal    57          2.95             0.49          7.82          1.59            0.72              SES Improved
Senthil 59 M 22.43 No Yes Yes Yes UA - CL III N No                 69% Normal    83          2.01              0.27         5.39          1.52            3.98                N Improved
Ramalingam 67 M 21.81 Yes No No Yes STEMI- IW N Lower IVS Inf wall 48% Mod    89          2.61              0.35         9.39          1.93            2.87                N Improved
Burhana 63 F 24.56 Yes No No No UA - CL III N No                 60% Normal    83          2.67              0.20         5.19         1.20           2.56                N Improved
Kuselan 72 M 21.73 No Yes No No NSTEMI N LV apex     54%       mild     80          3.11              0.27         10.9          1.92            2.08               N Improved
Raja kannan 47 M 27.89 Yes No Yes Yes STEMI- AS P IVS , IV apex      37%  Severe    80          2.71              0.45         5.98          1.52            2.80                N Improved
Muthukumari 69 F 19.02 No Yes No No STEMI- IW N Lower IVS Inf wall 48% Mod    83          2.61              0.27         5.39          1.52            2.87                N Improved
  
Ganesan 73 M 23.31 No Yes Yes No NSTEMI N No                 69% Normal    78          2.01              0.30         5.33          1.12            2.91                N Improved
Rukmaniammal 67 F 20.98 No Yes Yes No STEMI- IW P Lower IVS Inf wall 48% Mod    83          2.74              0.20         8.39          1.92            2.28                N Improved
Manikandan 50 M 26.43 Yes No Yes Yes STEMI- AS P IVS , IV apex      37%  Severe    83          2.61              0.27         5.39          1.52            2.87                N Improved
Suresh kumar 41 M 27.87 Yes Yes Yes Yes STEMI- Ext.AW P Ant, Lat wall   25%   severe    70          3.41              0.33         7.87          1.07            3.94                N Improved
Ramani 47 M 28.43 Yes Yes Yes Yes STEMI- AS P IVS , IV apex   34%  Severe    49          3.19             0.63          7.82          1.63            1.25              SES Improved
Marimuthu 71 M 22.56 No Yes No No NSTEMI N No                 65% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Ponnuthai 68 F 20.52 No Yes No No UA - CL III N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Kumaresan 51 M 26.65 Yes No No Yes UA - CL III P No                 73% Normal    75          3.97              0.34         5.39          1.87            0.57                N Improved
Amutha 57 F 23.09 Yes No No No STEMI- IW P Lower IVS Inf wall 48% Mild    60          1.29             0.62          7.31          1.39            3.83              SES Expired
Duraisamy 71 M 23.09 No Yes Yes No NSTEMI N No                 63% Normal    83          2.61              0.27         5.39          1.52            2.87                N Improved
Kumaran 65 M 21.78 No Yes No No NSTEMI N No                 68% Normal    83          2.48              0.35         5.34          1.57            2.17                N Improved
Parasuraman 70 M 22.71 No Yes Yes No STEMI- AS P IVS , IV apex      37%  Mod    78          3.61              0.17         9.39          1.57            2.39                N Improved
Janakiraman 65 M 24.54 Yes No No Yes STEMI- AS P IVS , IV apex      33%  Severe    83          2.89              0.27         5.41          1.09            2.10                N Improved
Saraswathy 67 F 23.56 Yes Yes No No STEMI- IW N Lower IVS Inf wall 41% Mod    90          2.61              0.26         5.30          1.52            2.27                N Improved
Karuppayi 56 F 25.92 Yes Yes Yes Yes STEMI- AS N IVS       47%  Mild    55          2.37            0.58           7.83           1.27           2.68               SES Improved
Thamaraikannan 49 M 27.55 Yes No Yes No UA - CL III P No                 63% Normal    61          3.80             0.42          6.90          1.49            2.51              SES Improved
Umavathy 51 F 23.21 Yes Yes No No STEMI- IW N Lower IVS Inf wall 48% Mild    83          2.69              0.20         5.30          1.02            2.08                N Improved
Eswaran 63 M 24.55 Yes No Yes No STEMI- AS N IVS , IV apex      37%  Severe    78          1.48              0.10         7.92          1.34            2.87                N Improved
